N
603538
vs
S
Shanghai Composite
Over the past 12 months, Ningbo Menovo Pharmaceutical Co Ltd has significantly outperformed Shanghai Composite, delivering a return of +60% compared to the Shanghai Composite's +24% growth.
Stocks Performance
603538 vs Shanghai Composite
Performance Gap
603538 vs Shanghai Composite
Performance By Year
603538 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Ningbo Menovo Pharmaceutical Co Ltd
Glance View
Ningbo Menovo Pharmaceutical Co., Ltd. engages in the research, development, testing, production, and sale of pharmaceutical products. The company is headquartered in Ningbo, Zhejiang and currently employs 2,473 full-time employees. The company went IPO on 2017-04-07. The Company’s products contain gastropathic medicine and cardiovascular medicine, which include anti-hypertension medicine, anti-hyperlipidemia medicine and anti-thrombus medicine. The firm distributes its products to both domestic and overseas markets.